Soltan M H, El-Gendi E, Imam H H, Fathi O
Department of Obstetrics and Gynaecology, El-Menia Faculty of Medicine, El-Menia University, Egypt.
Int J Health Sci (Qassim). 2007 Jul;1(2):229-36.
In the poor underdeveloped countries, anaemia is very common in pregnant women. Maternal mortality is four times higher in severely anaemic women than non-anaemic ones and postpartum haemorrhage (PPH) is the most common cause of death. Its main cause is uterine atony, which accounts for more than 70%. The objective of this study is to evaluate the use of sublingual misoprostol in different doses of 600, 800 and1000μg in management of the third stage of labor, with regards to blood loss and incidence of atonic postpartum haemorrhag (APPH).
Double blind randomized controlled study
One thousand and two hundred parturient were studied in a control and three study groups, each composed of 300 women. Methylergometrine 0.2 mg IM injection and sublingual misoprostol 600, 800 and 1000 μg tablets were given to women in control and the three study groups respectively, immediately after delivery.
Duration of the third stage of labour, Blood loss in the third stage of labour, Outcomes in anaemic compared to non-anaemic women, Incidance of atonic postpartum haemorrhage in different groups, Haemoglobin deficit after 24 hrs of delivery, Changes in the women's blood pressure during the study, Side effects of the drug, and, Women's acceptability of sublingual misoprostol administration.
Only significant reduction in blood loss and haemoglobin deficits were seen in the third stage of labour and after delivery in women used misoprostol doses of 800 μg and 1000 μg. The incidences of PPH in studied women and controls were almost similar, ranging between 2 and 3%. Similar results were seen in anaemic and non-anaemic women with a higher incidence of APPH in the non-misoprostol user anaemic women. Side effects of the drug were dose related.
Misoprostol in high dose may be used for managing third stage of labour to reduce maternal morbidity and mortality due to APPH particularly, in the poor underdeveloped countries where, facilities to deliver in health centers, purchase and store the oxytocic ampoules or medically trained persons are not readily available in all places. Benefits of large dose misoprostol outweigh its side effects.
在贫困不发达国家,孕妇贫血非常普遍。重度贫血孕妇的孕产妇死亡率是非贫血孕妇的四倍,产后出血(PPH)是最常见的死亡原因。其主要原因是子宫收缩乏力,占比超过70%。本研究的目的是评估不同剂量(600、800和1000μg)的舌下米索前列醇在第三产程管理中的应用,涉及失血情况和宫缩乏力性产后出血(APPH)的发生率。
双盲随机对照研究
对1200名产妇进行研究,分为一个对照组和三个研究组,每组300名女性。对照组和三个研究组的女性在分娩后立即分别给予0.2mg甲基麦角新碱肌肉注射以及600、800和1000μg的舌下米索前列醇片。
第三产程的持续时间、第三产程的失血量、贫血与非贫血女性的结局、不同组宫缩乏力性产后出血的发生率、分娩24小时后的血红蛋白下降情况、研究期间女性血压的变化、药物的副作用以及女性对舌下米索前列醇给药的接受度。
仅在使用800μg和1000μg米索前列醇剂量的女性中,第三产程及产后的失血量和血红蛋白下降情况有显著减少。研究女性和对照组中PPH的发生率几乎相似,在2%至3%之间。贫血和非贫血女性也有类似结果,未使用米索前列醇的贫血女性中APPH的发生率更高。药物的副作用与剂量相关。
大剂量米索前列醇可用于管理第三产程,以降低因APPH导致的孕产妇发病率和死亡率,特别是在贫困不发达国家,那里并非所有地方都具备在医疗中心分娩、购买和储存催产剂安瓿或有医学专业人员的条件。大剂量米索前列醇的益处大于其副作用。